#bone mineral density

Anjali Sharma, MD, and colleagues tested the bone density of 158 women living with HIV and 86 HIV-negative women.

This is especially the case for people globally who don’t have access to such newer regimens.

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

More research is needed to determine the potential risks and benefits of testosterone treatment in this population.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

A new large study compared the single-tablet regimen with an equivalent containing a different version of tenofovir.

Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.

Those who start antiretroviral (ARV) treatment for HIV soon after diagnosis experience a greater decline in bone mineral density.

HIV-positive people 50 and older who switched from Truvada to Descovy in a recent trial reaped health benefits.

Gilead Sciences has released results from three studies examining the effects of switching from the old tenofovir to the new version.

Previous research on bone loss during the first year on PrEP may have failed to consider poor adherence to the regimen.

After losing bone density during a year on PrEP, young men recouped their losses a year later but didn’t catch up with norms.

The FDA has approved Gilead Sciences’ fixed-dose combination tablet Descovy (emtricitabine/tenofovir alafenamide) for HIV treatment.